These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 35121108)
1. Fluoxetine ameliorates mucopolysaccharidosis type IIIA. Capuozzo A; Montefusco S; Cacace V; Sofia M; Esposito A; Napolitano G; Nusco E; Polishchuk E; Pizzo MT; De Risi M; De Leonibus E; Sorrentino NC; Medina DL Mol Ther; 2022 Apr; 30(4):1432-1450. PubMed ID: 35121108 [TBL] [Abstract][Full Text] [Related]
2. Neuronal-specific impairment of heparan sulfate degradation in Drosophila reveals pathogenic mechanisms for Mucopolysaccharidosis type IIIA. Webber DL; Choo A; Hewson LJ; Trim PJ; Snel MF; Hopwood JJ; Richards RI; Hemsley KM; O'Keefe LV Exp Neurol; 2018 May; 303():38-47. PubMed ID: 29408731 [TBL] [Abstract][Full Text] [Related]
3. Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications. Yogalingam G; Hopwood JJ Hum Mutat; 2001 Oct; 18(4):264-81. PubMed ID: 11668611 [TBL] [Abstract][Full Text] [Related]
4. Low-dose, continuous enzyme replacement therapy ameliorates brain pathology in the neurodegenerative lysosomal disorder mucopolysaccharidosis type IIIA. King B; Hassiotis S; Rozaklis T; Beard H; Trim PJ; Snel MF; Hopwood JJ; Hemsley KM J Neurochem; 2016 May; 137(3):409-22. PubMed ID: 26762778 [TBL] [Abstract][Full Text] [Related]
5. Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes. Fraldi A; Hemsley K; Crawley A; Lombardi A; Lau A; Sutherland L; Auricchio A; Ballabio A; Hopwood JJ Hum Mol Genet; 2007 Nov; 16(22):2693-702. PubMed ID: 17725987 [TBL] [Abstract][Full Text] [Related]
6. Exocytosis is impaired in mucopolysaccharidosis IIIA mouse chromaffin cells. Keating DJ; Winter MA; Hemsley KM; Mackenzie KD; Teo EH; Hopwood JJ; Brooks DA; Parkinson-Lawrence EJ Neuroscience; 2012 Dec; 227():110-8. PubMed ID: 23022219 [TBL] [Abstract][Full Text] [Related]
7. An Engineered Douek AM; Amiri Khabooshan M; Henry J; Stamatis SA; Kreuder F; Ramm G; Änkö ML; Wlodkowic D; Kaslin J Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073041 [TBL] [Abstract][Full Text] [Related]
8. Effect of high dose, repeated intra-cerebrospinal fluid injection of sulphamidase on neuropathology in mucopolysaccharidosis type IIIA mice. Mader KM; Beard H; King BM; Hopwood JJ Genes Brain Behav; 2008 Oct; 7(7):740-53. PubMed ID: 18518922 [TBL] [Abstract][Full Text] [Related]
9. Intracerebroventricular dosing of N-sulfoglucosamine sulfohydrolase in mucopolysaccharidosis IIIA mice reduces markers of brain lysosomal dysfunction. Magat J; Jones S; Baridon B; Agrawal V; Wong H; Giaramita A; Mangini L; Handyside B; Vitelli C; Parker M; Yeung N; Zhou Y; Pungor E; Slabodkin I; Gorostiza O; Aguilera A; Lo MJ; Alcozie S; Christianson TM; Tiger PMN; Vincelette J; Fong S; Gil G; Hague C; Lawrence R; Wendt DJ; Lebowitz JH; Bunting S; Bullens S; Crawford BE; Roy SM; Woloszynek JC J Biol Chem; 2022 Dec; 298(12):102625. PubMed ID: 36306823 [TBL] [Abstract][Full Text] [Related]
10. Reduction in Brain Heparan Sulfate with Systemic Administration of an IgG Trojan Horse-Sulfamidase Fusion Protein in the Mucopolysaccharidosis Type IIIA Mouse. Boado RJ; Lu JZ; Hui EK; Pardridge WM Mol Pharm; 2018 Feb; 15(2):602-608. PubMed ID: 29251941 [TBL] [Abstract][Full Text] [Related]
11. Systemic scAAV9.U1a.hSGSH Delivery Corrects Brain Biochemistry in Mucopolysaccharidosis Type IIIA at Early and Later Stages of Disease. Saville JT; Derrick-Roberts ALK; McIntyre C; Fuller M Hum Gene Ther; 2021 Apr; 32(7-8):420-430. PubMed ID: 33339477 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of enzyme dose and dose-frequency in ameliorating substrate accumulation in MPS IIIA Huntaway dog brain. King B; Marshall N; Beard H; Hassiotis S; Trim PJ; Snel MF; Rozaklis T; Jolly RD; Hopwood JJ; Hemsley KM J Inherit Metab Dis; 2015 Mar; 38(2):341-50. PubMed ID: 25421091 [TBL] [Abstract][Full Text] [Related]
13. Glycosaminoglycan levels and structure in a mucopolysaccharidosis IIIA mice and the effect of a highly secreted sulfamidase engineered to cross the blood-brain barrier. Maccari F; Sorrentino NC; Mantovani V; Galeotti F; Fraldi A; Volpi N Metab Brain Dis; 2017 Feb; 32(1):203-210. PubMed ID: 27585464 [TBL] [Abstract][Full Text] [Related]